Department of Biochemistry, All India Institute of Medical Sciences, Room No. 3009, Ansari Nagar, New Delhi, 110029, India.
Ann Hematol. 2010 Dec;89(12):1223-32. doi: 10.1007/s00277-010-1012-3. Epub 2010 Jun 22.
The diagnostic and prognostic significance of cathepsin B (CTSB) and L (CTSL) is well documented for solid tumors. However, their significance in acute leukemias is lacking. This study was planned to investigate expression and significance of these proteases in peripheral blood mononuclear cells (PBMCs) of patients with pediatric acute myeloid leukemia (AML). CTSL and CTSB activities were assayed in PBMCs of 24 children with AML and ten healthy controls by spectrofluorimetry. The mRNA levels of these proteases and their specific endogenous inhibitor cystatin C and transcriptional upregulator vascular endothelial growth factor (VEGF) were quantitated by real-time PCR. Correlation analysis of CTSL and CTSB activities/expression with their inhibitor/upregulator and event-free survival (EFS) was done using appropriate statistical tools. CTSL and CTSB protease activity and their mRNA expression were significantly higher in AML patients compared to controls (p ≤ 0.001). A strong positive correlation was observed between VEGF expression and CTSL (r = 0.812; p ≤ 0.001). Similarly, VEGF exhibited a strong positive correlation with CTSB (r = 0.501; p = 0.013). Cystatin expression though significantly high (p ≤ 0.001) in AML was negatively correlated with CTSL (r = -0.920; p ≤ 0.001) and CTSB (r = -0.580, p ≤ 0.001) expression. AML patients with higher CTSL and CTSB activity exhibited an inferior EFS (CTSL: p = 0.045; CTSB: p = 0.002) and overall survival (OS; CTSL: p = 0.05; CTSB: p = 0.004) compared to patients with lower levels of these proteases. This is the first report demonstrating increased expression of CTSL and CTSB in AML, mechanism of their increased expression in relation to VEGF, and their association with poor EFS and OS. These results suggest a potential utility of these proteases as prognostic markers for this malignancy.
组织蛋白酶 B(CTSB)和 L(CTSL)的诊断和预后意义在实体肿瘤中已有充分的记录。然而,它们在急性白血病中的意义尚不清楚。本研究旨在探讨这些蛋白酶在外周血单个核细胞(PBMC)中的表达及其在儿科急性髓细胞白血病(AML)中的意义。通过分光荧光法测定 24 例 AML 患儿和 10 例健康对照者 PBMC 中 CTSL 和 CTSB 的活性。实时 PCR 定量测定这些蛋白酶及其特异性内源性抑制剂胱抑素 C 和转录上调因子血管内皮生长因子(VEGF)的 mRNA 水平。使用适当的统计工具对 CTSL 和 CTSB 活性/表达与它们的抑制剂/上调因子和无事件生存(EFS)进行相关性分析。与对照组相比,AML 患者的 CTSL 和 CTSB 蛋白酶活性及其 mRNA 表达均显著升高(p≤0.001)。VEGF 表达与 CTSL 呈强正相关(r=0.812;p≤0.001)。同样,VEGF 与 CTSB 也呈强正相关(r=0.501;p=0.013)。虽然 AML 患者的胱抑素表达显著升高(p≤0.001),但与 CTSL(r=-0.920;p≤0.001)和 CTSB(r=-0.580,p≤0.001)表达呈负相关。与 CTSL(p=0.045)和总生存期(OS;CTSB:p=0.002)相比,具有较高 CTSL 和 CTSB 活性的 AML 患者 EFS 较差,与这些蛋白酶水平较低的患者相比。这是首次报道表明 CTSL 和 CTSB 在 AML 中的表达增加,其表达增加与 VEGF 相关的机制,以及它们与不良 EFS 和 OS 的关系。这些结果表明这些蛋白酶作为该恶性肿瘤预后标志物的潜在应用价值。